What's at stake: AFT Pharmaceuticals has delivered a strong 1H26 result, led by Australia, and its international business ramping up.
Background: The NZX-listed pharma, best known for its flagship pain relief product Maxigesic, is investing in geographic and product diversification, investing profits back into new business hubs offshore, and spending a healthy chunk on R&D.
Main players: AFT Pharmaceuticals, Dr Hartley Atkinson.
NZX-listed AFT Pharmaceuticals has delivered a strong first-half performance driven by offshore growth, particularly in Australia.
Revenue for the six months ending September 30, 2025 was a record $114.9 million, up 33% on the same period the prior year. It’s the tenth consecutive period of
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: AFT Pharmaceuticals has delivered a strong 1H26 result, led by Australia, and its international business ramping up.
Background: The NZX-listed pharma, best known for its flagship pain relief product Maxigesic, is investing in geographic and product diversification, investing profits back into new business hubs offshore, and spending a healthy chunk on R&D.
Main players: AFT Pharmaceuticals, Dr Hartley Atkinson.
